174 related articles for article (PubMed ID: 23982344)
1. Gold complexes inhibit the aggregation of prion neuropeptides.
Wang X; He L; Zhao C; Du W; Lin J
J Biol Inorg Chem; 2013 Oct; 18(7):767-78. PubMed ID: 23982344
[TBL] [Abstract][Full Text] [Related]
2. Influence of gold-bipyridyl derivants on aggregation and disaggregation of the prion neuropeptide PrP106-126.
Zhao C; Wang X; He L; Zhu D; Wang B; Du W
Metallomics; 2014 Nov; 6(11):2117-25. PubMed ID: 25273168
[TBL] [Abstract][Full Text] [Related]
3. Palladium complexes affect the aggregation of human prion protein PrP106-126.
Wang Y; Feng L; Zhang B; Wang X; Huang C; Li Y; Du W
Inorg Chem; 2011 May; 50(10):4340-8. PubMed ID: 21504185
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes.
Wang X; Zhang B; Zhao C; Wang Y; He L; Cui M; Zhu X; Du W
J Inorg Biochem; 2013 Nov; 128():1-10. PubMed ID: 23911565
[TBL] [Abstract][Full Text] [Related]
5. Regulation of aggregation behavior and neurotoxicity of prion neuropeptides by platinum complexes.
Wang X; Cui M; Zhao C; He L; Zhu D; Wang B; Du W
Inorg Chem; 2014 May; 53(10):5044-54. PubMed ID: 24787240
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation.
Wang X; Zhu D; Zhao C; He L; Du W
Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of sesquiterpene lactones on the aggregation and cytotoxicity of prion neuropeptide.
Huo Y; Huang X; Wang Y; Zhao C; Zheng T; Du W
Biochimie; 2023 Aug; 211():131-140. PubMed ID: 36963557
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 104 inhibited the fibrillization of prion peptide 106-126 and disassembled prion peptide 106-126 fibrils in vitro.
Liu YH; Han YL; Song J; Wang Y; Jing YY; Shi Q; Tian C; Wang ZY; Li CP; Han J; Dong XP
Int J Biochem Cell Biol; 2011 May; 43(5):768-74. PubMed ID: 21296677
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126.
Salmona M; Malesani P; De Gioia L; Gorla S; Bruschi M; Molinari A; Della Vedova F; Pedrotti B; Marrari MA; Awan T; Bugiani O; Forloni G; Tagliavini F
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):207-14. PubMed ID: 10432318
[TBL] [Abstract][Full Text] [Related]
10. Roles of Apigenin and Nepetin in the Assembly Behavior and Cytotoxicity of Prion Neuropeptide PrP106-126.
Huo Y; Zhao C; Wang Y; Wang S; Mu T; Du W
ACS Chem Neurosci; 2024 Jan; 15(2):245-257. PubMed ID: 38133816
[TBL] [Abstract][Full Text] [Related]
11. The role of prion peptide structure and aggregation in toxicity and membrane binding.
Rymer DL; Good TA
J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207
[TBL] [Abstract][Full Text] [Related]
12. Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation.
Corsaro A; Thellung S; Villa V; Principe DR; Paludi D; Arena S; Millo E; Schettini D; Damonte G; Aceto A; Schettini G; Florio T
Ann N Y Acad Sci; 2003 Dec; 1010():610-22. PubMed ID: 15033801
[TBL] [Abstract][Full Text] [Related]
13. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126.
Kanapathipillai M; Ku SH; Girigoswami K; Park CB
Biochem Biophys Res Commun; 2008 Jan; 365(4):808-13. PubMed ID: 18039468
[TBL] [Abstract][Full Text] [Related]
14. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126.
Jobling MF; Huang X; Stewart LR; Barnham KJ; Curtain C; Volitakis I; Perugini M; White AR; Cherny RA; Masters CL; Barrow CJ; Collins SJ; Bush AI; Cappai R
Biochemistry; 2001 Jul; 40(27):8073-84. PubMed ID: 11434776
[TBL] [Abstract][Full Text] [Related]
15. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126.
Jobling MF; Stewart LR; White AR; McLean C; Friedhuber A; Maher F; Beyreuther K; Masters CL; Barrow CJ; Collins SJ; Cappai R
J Neurochem; 1999 Oct; 73(4):1557-65. PubMed ID: 10501201
[TBL] [Abstract][Full Text] [Related]
16. Prion peptide 106-126 as a model for prion replication and neurotoxicity.
Singh N; Gu Y; Bose S; Kalepu S; Mishra RS; Verghese S
Front Biosci; 2002 Apr; 7():a60-71. PubMed ID: 11897566
[TBL] [Abstract][Full Text] [Related]
17. Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106-126.
Bergström AL; Chabry J; Bastholm L; Heegaard PM
Biochim Biophys Acta; 2007 Sep; 1774(9):1118-27. PubMed ID: 17707142
[TBL] [Abstract][Full Text] [Related]
18. Nonspecific prion protein-nucleic acid interactions lead to different aggregates and cytotoxic species.
Macedo B; Millen TA; Braga CA; Gomes MP; Ferreira PS; Kraineva J; Winter R; Silva JL; Cordeiro Y
Biochemistry; 2012 Jul; 51(27):5402-13. PubMed ID: 22691027
[TBL] [Abstract][Full Text] [Related]
19. Structural diversity and initial oligomerization of PrP106-126 studied by replica-exchange and conventional molecular dynamics simulations.
Ning L; Guo J; Bai Q; Jin N; Liu H; Yao X
PLoS One; 2014; 9(2):e87266. PubMed ID: 24586266
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35.
Hope J; Shearman MS; Baxter HC; Chong A; Kelly SM; Price NC
Neurodegeneration; 1996 Mar; 5(1):1-11. PubMed ID: 8731376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
